IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1301-1325 out of 1353.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

Public Release: 8-Jan-2016
Science Advances
Scientists find key driver for treatment of deadly brain cancer
A factor in how malignant tumors spread may also be a key to treatment.

Contact: Salk Communications
press@salk.edu
858-453-4100
Salk Institute

Public Release: 8-Jan-2016
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study led by Plymouth University has found.

Contact: Alan Williams
alan.williams@plymouth.ac.uk
0044-175-258-8004
University of Plymouth

Public Release: 7-Jan-2016
Cell Reports
New role of protein kinases in embryo development and cancer
A group of protein kinases have been found to play an important role in embryo development and may even be a potential cancer drug target, says research led by Queen Mary University of London and the Francis Crick Institute, UK.
Cancer Research UK, Barts Cancer Institute, HEFCE, Wellcome Trust, Royal Society

Contact: Joel Winston
j.winston@qmul.ac.uk
44-207-882-7943
Queen Mary University of London

Public Release: 7-Jan-2016
CA: A Cancer Journal for Clinicians
Cancer death rate continues steady drop
Steady reductions in smoking combined with advances in cancer prevention, early detection, and treatment have resulted in a 23 percent drop in the cancer death rate since its peak in 1991.

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 7-Jan-2016
American Journal of Medicine
Smokers diagnosed with pneumonia found to have higher risk of lung cancer
A new study from Tel Aviv University proposes that screening heavy smokers admitted to the hospital with community-acquired pneumonia could facilitate the early diagnosis of lung cancer and thereby reduce the incidence of mortality.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Public Release: 7-Jan-2016
JAMA Oncology
Higher cancer death rate associated with solid-organ transplant recipients
In solid-organ transplant recipients, the cancer death rate was higher than in the general population in a new study from Ontario, Canada, published online by JAMA Oncology.

Contact: Nancy N. Baxter
baxtern@smh.ca
The JAMA Network Journals

Public Release: 7-Jan-2016
Molecular Cell
Scientist identifies energy sensor as potential target for cancer drugs
An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs.

Contact: Cindy Starr
cindy.starr@uc.edu
513-558-3505
University of Cincinnati Academic Health Center

Public Release: 7-Jan-2016
Proceedings of the National Academy of Sciences
Epigenetic regulation of metastatic breast cancer progression may guide prognosis and future therapy
A gene that plays a role in the development of breast cancer to metastatic disease has been identified which may help to predict disease progression and serve as a target for the development of future breast cancer therapies.
Susan G. Komen for the Cure, National Institutes of Health, BU Genome Science Institute, Research Promotion Foundation of Cyprus

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 7-Jan-2016
Clinical Cancer Research
Blocking melanoma's escape: Avatars break theraping resistance in relapsed cancers
By utilizing a revolutionary method that allows mice to serve as 'avatars' for patients, scientists at The Wistar Institute have shown that a previously ineffective targeted drug for melanoma may actually be quite potent in halting the progression of disease in certain patients.
Novartis, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 7-Jan-2016
Nature Chemistry
A 'printing press' for nanoparticles
Gold nanoparticles have unusual properties, which scientists are seeking to put to use in a range of technologies. Some of the most interesting properties emerge when nanoparticles are brought close together. But a major challenge has been finding ways to assemble these bits of gold while controlling the three-dimensional shape of their arrangement. In results reported in Nature Chemistry, researchers from McGill University outline a new technique.
Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation, Centre for Self-Assembled Chemical Structures, Canada Research Chairs Program, Canadian Institutes of Health Research

Contact: Chris Chipello
christopher.chipello@mcgill.ca
514-398-4201
McGill University

Public Release: 6-Jan-2016
Human Molecular Genetics
Cancer drug shows promise for treating Duchenne muscular dystrophy
A drug commonly used to treat leukemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
Muscular Dystrophy UK, Medical Research Council, Duchenne Parent Project NL

Contact: Beck Lockwood
beck@campuspr.co.uk
University of Sheffield

Public Release: 6-Jan-2016
Cell Metabolism
Scientists root out the 'bad seeds' of liver cancer
Researchers have found the 'bad seeds' of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new USC study has found. The key to disrupting chemo-resistant stem cells that become liver tumors from multiplying is to target the stem cell marker NANOG, said Keigo Machida, senior author.
National Institutes of Health, Animal Core, Morphology Core, and Pilot Project Program, Non-Parenchymal Liver Cell Core, Research Scholar Grant, American Cancer Society

Contact: Zen Vuong
zvuong@usc.edu
213-300-1381
University of Southern California

Public Release: 6-Jan-2016
The Lancet
Winship multiple myeloma study in The Lancet
Winship multiple myeloma expert Sagar Lonial, M.D., played a key role in the testing of daratumumab (trade name Darzalex), which received accelerated approval from the US FDA in November 2015.
Janssen Biotech

Contact: Catherine Williams
catherine.s.williams@emory.edu
404-778-5848
Emory Health Sciences

Public Release: 6-Jan-2016
Science Translational Medicine
Early trial shows injectable agent illuminates cancer during surgery
Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon's ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology and Lumicell Inc.
American Society of Clinical Oncology, National Institutes of Health, NIH/National Cancer Institute, NIH/National Center for Advancing Translational Science, Duke Comprehensive Cancer Center

Contact: Samiha Khanna
samiha.khanna@duke.edu
919-419-5069
Duke University Medical Center

Public Release: 6-Jan-2016
Contemporary Clinical Trials Communications
New open access journal highlights methods and clinical trial results
The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials.

Contact: Jason Awerdick
j.awerdick@elsevier.com
212-633-3103
Elsevier

Public Release: 6-Jan-2016
The BMJ
Cancer screening has never been shown to 'save lives,' argue experts
Cancer screening has never been shown to 'save lives' as advocates claim, argue experts in The BMJ today.

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ

Public Release: 6-Jan-2016
16th IASLC World Conference on Lung Cancer
PLOS ONE
International CTCA study shows statins could be effective against small cell lung cancer
Researchers at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer. The study of 876 late-stage SCLC patients, published today in the scientific journal PLOS ONE, showed that statins, a class of drugs primarily used to lower cholesterol in patients at risk for heart disease, appeared to provide an increase in overall survival.
Hungarian Society of Pulmonology 2015/Lung Cancer Research Scholarship

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
Cancer Treatment Centers of America

Public Release: 6-Jan-2016
Lung cancer clinical trial finds lung function without additional imaging
A newly NIH funded clinical trial by University of Colorado Cancer Center investigators and collaborators is evaluating a new method for pinpointing and sparing healthy lung tissue during lung cancer radiotherapy.
National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 6-Jan-2016
Cancer Discovery
New drug may overcome treatment resistance in a high-risk children's cancer
Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. The 'unparalleled' strength of an ALK inhibitor in their preclinical studies, say the researchers, justifies fast-tracking the drug into pediatric clinical trials this year.
National Institutes of Health, US Army Peer Reviewed Medical Research Program

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia

Public Release: 6-Jan-2016
Human Gene Therapy
Proposed link between liver cancer and adeno-associated virus challenged in human gene therapy
The conclusion drawn from a recent study that insertion of adeno-associated virus 2 into human DNA causes mutations leading to the development of hepatocellular carcinoma was resoundingly rejected by leading researchers in the fields of gene therapy and molecular genetics. Calling the conclusions of the study authors 'an enormous leap from their data,' the team of researchers challenge details of the experimental methods, interpretation of the findings, and limitations of the study design in an Editorial published in Human Gene Therapy.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 6-Jan-2016
Genetics
DNA research offers clues on cell mutation
A Colorado State University team has found that RNA plays a new and important role in the DNA repair process.
NIH/Division of Intramural Research, NIH/National Institute of Environmental Health Sciences, Boettcher Foundation/Webb-Waring Biomedical Research Award, CNPq/Brazil, National Science Foundation/REU

Contact: Mary Guiden
mary.guiden@colostate.edu
970-491-6892
Colorado State University

Public Release: 6-Jan-2016
American Journal of Medicine
New FAU study suggests benefits of regular mammography extend to the elderly
Although a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities. A new study shows that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.

Contact: Gisele Galoustian
ggaloust@fau.edu
561-297-2676
Florida Atlantic University

Public Release: 6-Jan-2016
PLOS ONE
UC San Diego researchers link higher risk of leukemia to low sunlight and vitamin D
Epidemiologists at University of California, San Diego School of Medicine report that persons residing at higher latitudes, with lower sunlight/ultraviolet B (UVB) exposure and greater prevalence of vitamin D deficiency, are at least two times at greater risk of developing leukemia than equatorial populations.
University of California - San Diego Department of Family Medicine and Public Health

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 5-Jan-2016
Proceedings of the National Academy of Sciences
Novel RNA delivery system may treat incurable blood cancers
Mantle Cell Lymphoma is considered the most aggressive known blood cancer, and available therapies are scarce. A new study by Tel Aviv University researchers offers tangible hope of curing the currently incurable cancer -- and others like it.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Public Release: 5-Jan-2016
ecancermedicalscience
Association for Cancer Physicians releases cancer patient strategy for UK
The Association for Cancer Physicians, which represents and supports medical oncologists in the UK, has published a new strategy for improving cancer patient services and outcomes.

Contact: Audrey Nailor
audrey@ecancer.org
44-011-740-33098
ecancermedicalscience

Showing releases 1301-1325 out of 1353.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

  Search News Releases

     

 

EurekAlert!